Myeloid/lymphoid neoplasms with eosinophilia/ basophilia and ETV6-ABL1 fusion: cell-of-origin and response to tyrosine kinase inhibition

Haematologica. 2021 Feb 1;106(2):614-618. doi: 10.3324/haematol.2020.249649.
No abstract available

Publication types

  • Letter
  • Research Support, N.I.H., Extramural

MeSH terms

  • Core Binding Factor Alpha 2 Subunit
  • Eosinophilia* / drug therapy
  • Fusion Proteins, bcr-abl
  • Humans
  • Myeloproliferative Disorders* / drug therapy
  • Myeloproliferative Disorders* / genetics
  • Neoplasms*
  • Oncogene Proteins, Fusion / genetics
  • Protein Kinase Inhibitors / therapeutic use
  • Protein-Tyrosine Kinases / genetics

Substances

  • Core Binding Factor Alpha 2 Subunit
  • Oncogene Proteins, Fusion
  • Protein Kinase Inhibitors
  • TEL-AML1 fusion protein
  • Protein-Tyrosine Kinases
  • Fusion Proteins, bcr-abl